Several ICI‐responsiveness biomarkers have been proposed, including the tumoral expression of PD‐L1,4 tumor‐infiltrating lymphocytes (TILs),5 tumor mutational burden (TMB),6, 7 DNA mismatch‐repair deficiency,8 and gene signatures reflecting preexisting adaptive immunity 9; however, each of these biomarkers has limited utility. The gene discussed is CD274; the disease is neoplasm.